<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">The implication of birth defects in infected pregnant mothers, neurological illness in adults as well as the possibility of sexual transmission has intensified efforts to develop a vaccine for ZIKV, as currently there is no approved vaccine for the virus. Great strides have already been made and several recent reports have demonstrated the efficacy of both inactivated ZIKV vaccine as well as of prM/E proteins expressed 
 <italic>via</italic> DNA or adenoviral vectors in mice and monkey models, and most recently, a single dose of nanoparticle-encapsulated mRNA vaccine encoding prM-E protein also induced strong and durable protection in mice and monkeys (
 <xref rid="bb0005" ref-type="bibr">Abbink et al., 2016</xref>, 
 <xref rid="bb0035" ref-type="bibr">Dowd et al., 2016</xref>, 
 <xref rid="bb0075" ref-type="bibr">Larocca et al., 2016</xref>, 
 <xref rid="bb0105" ref-type="bibr">Pardi et al., 2017</xref>). Moreover, human neutralizing antibodies have been shown to protect mice against ZIKV infection (
 <xref rid="bb0120" ref-type="bibr">Sapparapu et al., 2016</xref>). Although these results are encouraging, efficacy has so far not been demonstrated against human subjects or human cells 
 <italic>in vivo</italic>.
</p>
